Nouveaux traitements de l'hépatite C: aspects pharmacologiques et potentiel d'interaction [New hepatitis C treatments: pharmacological considerations and potential for drug interactions].

Details

Ressource 1Request a copy Sous embargo indéterminé.
State: Public
Version: Final published version
Serval ID
serval:BIB_137CFB3E0910
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Nouveaux traitements de l'hépatite C: aspects pharmacologiques et potentiel d'interaction [New hepatitis C treatments: pharmacological considerations and potential for drug interactions].
Journal
Revue Médicale Suisse
Author(s)
Chtioui H., Buclin T., Moradpour D.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
09/2014
Volume
10
Number
440
Pages
1600-4, 1606
Language
french
Abstract
Progress in the understanding of the hepatitis C virus life cycle allowed the development of new, very promising antiviral therapies. Although these new drugs have a favourable profile in terms of efficacy, tolerance and interaction potential, their prescription in the setting of comedication and impaired renal or hepatic function remains a challenge. Here, we provide a summary of pharmacological considerations, focusing on sofosbuvir, simeprevir and daclatasvir. A better understanding of their metabolic pathways and transporters may help the prescriber to identify and manage drug interactions especially in patients under immunosuppressive or anti-HIV therapy. Recommendations for the prescription of these drugs in specific situations are also discussed.
Keywords
Antiviral Agents/pharmacology, Antiviral Agents/therapeutic use, Drug Interactions, Hepatitis C, Chronic/drug therapy, Heterocyclic Compounds, 3-Ring/pharmacology, Heterocyclic Compounds, 3-Ring/therapeutic use, Humans, Imidazoles/pharmacology, Imidazoles/therapeutic use, Protease Inhibitors/pharmacology, Protease Inhibitors/therapeutic use, Sulfonamides/pharmacology, Sulfonamides/therapeutic use, Uridine Monophosphate/analogs & derivatives, Uridine Monophosphate/pharmacology, Viral Nonstructural Proteins/antagonists & inhibitors
Pubmed
Create date
11/11/2014 13:37
Last modification date
20/08/2019 13:42
Usage data